Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. Starboard stopped short of ...
Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...
Activist investor Starboard is backing down in its fight at Pfizer after seeing little chance of winning board seats or rousing enough shareholder pressure to force out its CEO. A deadline to ...
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter. Starboard did not nominate any directors ...
Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of ...
Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...
Starboard Value LP bought a new stake in shares of Pfizer in the 4th quarter valued at $407,730,000. Raymond James Financial Inc. bought a new stake in shares of Pfizer in the 4th quarter valued ...
Pfizer got a reprieve in late January when Starboard did not nominate its own slate of directors to the company’s board, but the activist could still agitate for changes in 2026. Among Pfizer ...
(Bloomberg) -- Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter. Starboard did not nominate ...